Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Robert Gottlieb, Ajay Nirula, Peter Chen, et al.
JAMA (2021) Vol. 325, Iss. 7, pp. 632-632
Open Access | Times Cited: 884

Showing 1-25 of 884 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 130-135
Open Access | Times Cited: 2239
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1638
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1106
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2384-2393.e12
Open Access | Times Cited: 991
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 724
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter Halfmann, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 490-495
Open Access | Times Cited: 708
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Robert Gottlieb, Carlos Vaca, Roger Paredes, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 4, pp. 305-315
Open Access | Times Cited: 633
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Pengfei Wang, Ryan G. Casner, Manoj S. Nair, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 747-751.e4
Open Access | Times Cited: 613
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu, Irit Avivi, Anat Aharon, et al.
Blood (2021) Vol. 137, Iss. 23, pp. 3165-3173
Open Access | Times Cited: 602
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 396
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Sanjay Ramakrishnan, Dan V. Nicolau, Beverly Langford, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 7, pp. 763-772
Open Access | Times Cited: 381
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
Emanuele Andreano, Giulia Piccini, Danilo Licastro, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 36
Open Access | Times Cited: 359
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 320
COVID-19: breaking down a global health crisis
Saad I. Mallah, Omar Ghorab, Sabrina Al-Salmi, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 305
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 209-221
Open Access | Times Cited: 297
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
Science Translational Medicine (2021) Vol. 14, Iss. 628
Open Access | Times Cited: 297
A guide to immunotherapy for COVID-19
Frank L. van de Veerdonk, Evangelos J. Giamarellos‐Bourboulis, Peter Pickkers, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 39-50
Open Access | Times Cited: 276
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Frauke Muecksch, Zijun Wang, Alice Cho, et al.
Nature (2022) Vol. 607, Iss. 7917, pp. 128-134
Open Access | Times Cited: 268
Page 1 - Next Page

Scroll to top